Vascular Biogenics (NASDAQ:VBLT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
VBLT has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Vascular Biogenics in a report on Tuesday, November 7th. Chardan Capital raised their price target on Vascular Biogenics from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, November 6th. Finally, ValuEngine raised Vascular Biogenics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $15.67.
Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.04). equities analysts anticipate that Vascular Biogenics will post -0.9 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of VBLT. First Eagle Investment Management LLC grew its position in shares of Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock valued at $4,256,000 after purchasing an additional 727,273 shares in the last quarter. Knoll Capital Management LP purchased a new position in Vascular Biogenics in the third quarter worth approximately $4,406,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Vascular Biogenics in the second quarter worth approximately $1,844,000. Macquarie Group Ltd. purchased a new position in Vascular Biogenics in the second quarter worth approximately $1,521,000. Finally, Turner Investments L.P. purchased a new position in Vascular Biogenics in the second quarter worth approximately $1,007,000. Hedge funds and other institutional investors own 6.64% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.